Drug intelligence / Profile preview

EO2318

Development stage: Unknown
Lead developer: Enterome
Modality: Vaccines & Immunotherapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Peptides, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Subcutaneous

Overview

EO2318 is an innovative OncoMimic peptide-based immunotherapy developed by Enterome, specifically targeting mismatch repair proficient (pMMR) and microsatellite stable (MSS) colorectal adenocarcinoma. The drug is based on Enterome's proprietary Mimicry platform, which identifies bacterial peptides from the human gut microbiome that share high structural similarity with tumor-associated antigens (TAAs). By administering these synthetic bacterial mimics, EO2318 aims to activate and expand pre-existing memory T cells that were originally primed by the microbiome, redirecting them to recognize and eliminate cancer cells. This approach is designed to overcome the low immunogenicity typically associated with MSS CRC, which often fails to respond to standard checkpoint inhibitors. EO2318 is currently being evaluated in clinical trials in combination with immune checkpoint inhibitors and standard-of-care chemotherapy to enhance anti-tumor immune responses.

Targets

Tumor-associated antigens mimicked by EO2318-derived peptidesTCR-EO2318-MHC (T-cell receptor (TCR) on T lymphocytes recognizing EO2318-derived peptide–MHC complexes)

Beyond the preview

Go deeper on EO2318.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EO2318.

Explore the full profile